NIFEDIPINE TREATMENT FOR RECURRENT MISCARRIAGE IN WOMEN WITH ABNORMAL UTERINE ARTERY DOPPLER PARAMETERS | ||||
ALEXMED ePosters | ||||
Article 4, Volume 4, Issue 4, December 2022, Page 44-45 | ||||
Document Type: Preliminary preprint short reports of original research | ||||
DOI: 10.21608/alexpo.2022.179104.1526 | ||||
View on SCiNiTO | ||||
Authors | ||||
Nermeen Saad El-Beltagy1; Tarek Mokhtar Toppozada2; Omar Aassar3; Sara Hazem Hassan4; Rana Mustafa Hegazy Mohamed 5 | ||||
1Department of Obstetrics and Gynecology, Alexandria Faculty of Medicine, Alexandria University | ||||
2Department of Obstetrics and Gynecology, Alexandria Faculty of Medicine, Alexandria University | ||||
3Lecturer in Radiodiagnosis, Faculty of Medicine, University of Alexandria, | ||||
4Student at Alexandria Faculty of Medicine, Alexandria University | ||||
5Department of Obstetrics and gynecology, Alexandria Faculty oF Medicine, Alexandria University | ||||
Abstract | ||||
INTRODUCTION: Recurrent miscarriage, which is defined as three or more consecutive miscarriages before the 24th week of gestation affects 0.5–1% of couples. By studying uterine artery blood flow using Doppler ultrasound, elevated uterine resistance is associated with recurrent pregnancy loss. Nifedipine is a calciun channel blocker which decreases peripheral artery vascular resistance. AIM OF THE WORK: The main aim of this study was to assess the effect ofnifedipine in improving uterine artery Doppler parameters during the luteal phase, prior to pregnancy and the enhancement of pregnancy outcome in patients with recurrent miscarriage. SUBJECTS AND METHODS: This prospective randomized clinical trial was conducted on 50 women, 25 as intervention group (nifedipine group) and 25 as placebo group, were recruited from EL-Shatby university hospital and private centers after fulfilling the inclusion and exclusion criteria. The duration of the study was performed from November 2020 to January 2022. RESULTS: The uterine arterial blood flow indices has decreased significantly after 24 weeks of nifedipine and at 12 and 24 weeks of pregnancy with statistically significant difference with control group (p < 0.05). | ||||
Keywords | ||||
NIFEDIPINE; DOPPLER; MISCARRIAGE | ||||
Supplementary Files
|
||||
Statistics Article View: 87 |
||||